Among adults with type 2 diabetes, women are twice as likely as men to have coronary heart disease, according to a scientific statement from the American Heart Association.

An FDA advisory committee rejected Merck’s claims that the combination of ezetimibe and simvastatin (Vytorin) reduces the risk of cardiovascular events such as MI and stroke compared with simvastatin alone in patients with coronary heart disease.

Physicians and patients should share in the decision-making and should each be held accountable for adhering to medications, according to updated performance measures the American College of Cardiology (ACC) and American Heart Association (AHA) released on Dec. 14 for lipid management in secondary prevention.

A systematic review found that patients with kidney disease were underrepresented in clinical trials of cardiovascular disease interventions.

A mobile stroke treatment unit (MSTU) equipped with telemedicine, including a neuroradiologist remotely assessing images obtained by mobile CT, may be an effective way to provide accurate care, according to a recent study published in JAMA Neurology that put Cleveland Clinic's unit to the test.

Even if clinicians prescribe PCSK9 inhibitors to lower cholesterol, it’s uncertain how many patients will adhere to the treatment regimen.

Nearly half of adults in the U.S. who were eligible for cholesterol-lowering medications from 2005 to 2012 did not receive treatment, according to a Centers for Disease Control and Prevention (CDC) report released on Dec. 4.

The proportion of U.S. adults with high total cholesterol and low high-density lipoprotein (HDL) cholesterol has decreased in recent years, according to data released by the Centers for Disease Control and Prevention on Dec. 1.